Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta-lactose is an anomeric form of lactose, a disaccharide sugar composed of D-galactose and D-glucose. While alpha-lactose is more common, beta-lactose is highly water-soluble and is widely utilized as a pharmaceutical excipient, particularly as a filler and binder in direct compression tablet formulations. Beyond its role as an inactive ingredient, beta-lactose acts as a carbohydrate ligand that binds to galectins, such as Galectin-3 and Galectin-9, which are involved in cell adhesion, inflammation, and immune checkpoint regulation. It is also investigated for its prebiotic effects on the gut microbiome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-lactose.